IVA.PA FR Equity☆

Pricefull chart →

Mkt cap $832.4M · 1Y +42.5% · Off 52W high −36.8% · Vol (1Y) 65.1%

Key fundamentalsfull statements →

Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases, based in France and operating internationally. Its lead candidate, Lanifibranor, is a PPAR agonist in a Phase 3 trial for MASH, and it is also developing Odiparcil for mucopolysaccharidoses and a preclinical TGF-ß program for idiopathic pulmonary fibrosis. The company is headquartered in Daix, France.

Snapshot

Headline riskfull risk →

Peers

No same-industry peers in the universe for IVA.PA.